| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Nifurpirinol targets bacterial nitroreductase (NTR) enzymes. As a prodrug, it is activated by NTR-mediated reduction, producing cytotoxic metabolites that kill NTR-expressing cells. This makes it useful for targeted cell ablation in transgenic models. The compound also has antimicrobial activity against various pathogens. Its selectivity for NTR-expressing cells enables precise cell ablation in research applications.
|
|---|---|
| ln Vitro |
In vitro, Nifurpirinol is activated by bacterial nitroreductase to produce cytotoxic metabolites. It shows pronounced cytotoxicity in cells expressing NTR. Treated cells show increased cell debris and large cells with enlarged cytoplasm and irregular nuclei, indicative of apoptosis. The compound is more potent than metronidazole for NTR-mediated cell ablation. Detailed in vitro data are available in the primary literature.
|
| ln Vivo |
In vivo, Nifurpirinol is used as a prodrug for cell ablation in NTR-expressing transgenic zebrafish models. It selectively disrupts the activity of collagen-producing 1α2 cells in the Fli/colRN zebrafish line. The compound is effective in controlling diseases like columnaris and fin rot in fish farming. Due to potential toxicity and regulatory concerns, its use is monitored.
|
| Enzyme Assay |
In vitro NTR activation assays for Nifurpirinol typically use recombinant NTR enzyme or cell lysates from NTR-expressing cells. The compound is dissolved in DMSO and diluted in assay buffer (50 mM Tris-HCl, pH 7.5, 1 mM NADPH). Reactions are initiated by adding NTR and incubated at 37°C for 30-60 minutes. Product formation is monitored by absorbance or fluorescence. Cytotoxicity is assessed in NTR-expressing cell lines by MTT or LDH release assays. IC₅₀ values are calculated from dose-response curves. Controls include vehicle and metronidazole.
|
| Cell Assay |
For cell-based assays, NTR-expressing cell lines (e.g., HEK-293 or HeLa cells stably transfected with NTR) are cultured in DMEM with 10% FBS and selection antibiotics. Cells are seeded in 96-well plates and treated with Nifurpirinol at various concentrations for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. Apoptosis is assessed by flow cytometry or caspase assays. Cell morphology is examined microscopically. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Nifurpirinol is typically administered to zebrafish or other fish species via water immersion or injection. For transgenic models, NTR expression is driven by tissue-specific promoters. Cell ablation is assessed by fluorescence microscopy or histology. For disease control studies in fish, the compound is added to water or feed. Efficacy is assessed by mortality reduction or pathogen load. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Nifurpirinol (C₁₂H₁₀N₂O₄, MW ~246) is a nitroaromatic antibiotic and NTR prodrug. The compound is activated by NTR-mediated reduction. Pharmacokinetic properties in fish have been characterized. The compound is used in aquaculture research. Due to toxicity concerns, its use is regulated.
|
| Toxicity/Toxicokinetics |
Nifurpirinol is acutely toxic to milkfish species. The compound shows pronounced cytotoxicity upon NTR activation. Due to potential toxicity and regulatory concerns, its use is monitored. The compound is for research use only and not intended for human therapeutic applications. Standard safety precautions should be followed.
|
| Additional Infomation |
Nifurpirinol is a C-nitro compound belonging to the furan class of compounds.
Nifurpirinol (P-7138) is a research-grade NTR prodrug for cell ablation studies in transgenic models. Its primary applications include developmental biology, neuroscience, and aquaculture research. The compound is not approved for clinical use. It is commercially available from chemical suppliers for research purposes only. Its mechanism involves NTR-mediated activation to cytotoxic metabolites. |
| Molecular Formula |
C12H10N2O4
|
|---|---|
| Molecular Weight |
246.222
|
| Exact Mass |
246.064
|
| CAS # |
13411-16-0
|
| PubChem CID |
6436061
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.412 g/cm3
|
| Boiling Point |
416.3ºC at 760 mmHg
|
| Melting Point |
170-171°
|
| Flash Point |
205.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.695
|
| LogP |
2.768
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCC1C=CC=C(/C=C/C2=CC=C([N+]([O-])=O)O2)N=1
|
| InChi Key |
JQKHJQJVKRFMCO-SNAWJCMRSA-N
|
| InChi Code |
InChI=1S/C12H10N2O4/c15-8-10-3-1-2-9(13-10)4-5-11-6-7-12(18-11)14(16)17/h1-7,15H,8H2/b5-4+
|
| Chemical Name |
[6-[(E)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl]methanol
|
| Synonyms |
P-7138; P 7138; Nifurpirinol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 20.83 mg/mL (~84.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 + to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0614 mL | 20.3070 mL | 40.6141 mL | |
| 5 mM | 0.8123 mL | 4.0614 mL | 8.1228 mL | |
| 10 mM | 0.4061 mL | 2.0307 mL | 4.0614 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
